GlassScriptPhysician profile
Yash Suthar
NPI 1336596428
$10,274.82
in general payments reported to CMS, 2019-2025
36 companies · $366 in 2025
The $366 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $1,880 · 2021: $1,271 · 2022: $2,743 · 2023: $2,611 · 2024: $1,248 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,225.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,675.46 | 2019-2023 | Mitraclip, Diamondback Peripheral, Diamondback Coronary |
| Boston Scientific Corporation | $1,444.37 | 2021-2024 | Opticross, Synergy, Avvigo Guidance System |
| Shockwave Medical, INC | $957.36 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Cardiovascular Systems INC. | $848.68 | 2022-2023 | Diamondback Peripheral, Diamondback Coronary |
| Atricure, INC. | $674.62 | 2022-2024 | |
| Medtronic, INC. | $581.19 | 2021-2024 | Corevalve Evolut R, Hawkone, In.Pact Admiral |
| E.R. Squibb & Sons, L.L.C. | $401.41 | 2021-2025 | Eliquis, Camzyos |
| Pfizer INC. | $324.81 | 2019-2025 | |
| Abiomed | $302.98 | 2023-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.71 | 2023-2025 | Jardiance |
| Amgen INC. | $187.10 | 2021-2025 | Repatha, Repatha |
| Terumo Medical Corporation | $171.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $166.08 | 2023-2025 | |
| Preventice Services, LLC | $149.86 | 2021 | |
| Chiesi USA, INC. | $142.52 | 2022-2023 | Kengreal |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yash Suthar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.